Related Experiment Video
Updated: Jul 8, 2026

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
Published on: May 15, 2021
Cytocidal effect and DNA damage of nedaplatin: a mathematical model and analysis of experimental data
Y Miyagi1, K Kawanishi, Y Miyagi
1Department of Obstetrics and Gynecology, Okayama University Medical School, Shikata-cho 2-5-1, Okayama City, Okayama 700-8558, Japan. miyagi@mac.com
Purpose:
Cell cycle non-specific anticancer agents such as cis-diamminedichloroplatinum(II) are believed to depend linearly on the value of the area under the drug concentration time curve, which is supported by a mathematical model. However, the quantitative non-linear phenomena of both the cytocidal effect and DNA crosslink formation by cisdiammine(glycolato)platinum (nedaplatin) have been shown in vitro. Therefore, we developed a new mathematical model to explain these phenomena.
Methods:
We assumed that nedaplatin enters intracellular fluid from medium through simple diffusion to form DNA crosslinks that kill cells. We developed a mathematical model to represent this assumption using differential equations that we then solved using an original computer program. The calculated results were compared with the experimental data.
Results:
The drug's simple diffusion rate constant, the DNA crosslink formation rate constant, and the crosslink-dependent cell death rate constant in the model were 1.8 x 10(-14) (l h-1), 1.6 x 10(8) (l mol-1/2 h-1), 5.45 x 10(1) (mol-1), respectively. The model fits the experimental results statistically. The model also demonstrated theoretical proof that continuous exposure at a low dose was superior to the short exposure at a high dose seen in published experimental data.
Conclusions:
We developed a mathematical model to describe the non-linear pharmacodynamic effect of nedaplatin in vitro. This model may provide a novel drug infusion procedure for cancer patients.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

